 Teva Pharmaceutical Industries Ltds NYSE: TEVA Q1 sales reached 3.66 billion, shrinking 8 YY, missing the consensus of 3.75 billion. The decrease is mainly due to lower revenues from generic products in North America and Copaxone, partially offset by higher revenues from. 